
Mixed Results From Phase 3 Data for AR1001 in Alzheimer Disease
Key Takeaways
- POLARIS-AD randomized 1535 participants to once-daily AR1001 30 mg or placebo for 52 weeks, with dual primary analyses in overall and prespecified monotherapy populations.
- In patients not receiving acetylcholinesterase inhibitors or memantine, AR1001 improved CDR-SB by 0.44 versus placebo (P = .0266), but overall CDR-SB was nonsignificant.
New phase 3 data for a PDE-5 inhibitor in Alzheimer disease.
An investigational oral phosphodiesterase 5 inhibitor, AR1001, met its primary efficacy objective in the prespecified monotherapy population of the phase 3 POLARIS-AD trial in early Alzheimer disease but did not separate from placebo in the overall population, according to topline results from AriBio.¹ Among patients not taking an acetylcholinesterase inhibitor or memantine at baseline, AR1001 30 mg reduced change on the Clinical Dementia Rating–Sum of Boxes (CDR-SB) by 0.44 points vs placebo at week 52 (P = .0266), which the company described as a 31% slowing of clinical decline.¹
The global, randomized, double-blind, placebo-controlled trial began in December 2022 and enrolled 1535 participants across 13 countries. Participants received AR1001 30 mg or placebo once daily for 52 weeks. The primary end point was change in CDR-SB from baseline to week 52 in 2 prespecified primary populations: the overall population (n = 1535) and the monotherapy population (n = 604). A total of 1349 participants (87.9%) completed the double-blind period, and 1284 of them (95.2%) entered the open-label extension.¹
In the overall population, the CDR-SB difference was 0.11 points (P = .4015), numerically favoring AR1001 but not significant. In the monotherapy population, the difference on the Mini-Mental State Examination was 0.7 points (P = .0232), and the difference on the Alzheimer Disease Assessment Scale–Cognitive Subscale 13 was 1.16 points (P = .0798). Other secondary measures numerically favored AR1001 in both populations. Cerebrospinal fluid cyclic guanosine monophosphate differed from placebo at week 52 in both populations (overall, P < .0001; monotherapy, P = .0058). Cerebrospinal fluid phosphorylated tau 217 was lower with AR1001 by 5.34 pg/mL in the monotherapy population (P = .0402) but not significantly so overall (3.52 pg/mL; P = .1784). The amyloid-β 42/40 ratio did not differ at 52 weeks.¹
Treatment-emergent adverse events occurred in 69.0% of the AR1001 group and 66.4% of the placebo group, and serious events in 10.0% and 9.8%, respectively. Fatal events occurred in 4 participants (0.5%) vs 2 (0.3%). Diarrhea (7.7% vs 4.4%), falls (7.3% vs 5.9%), and dizziness (6.1% vs 3.1%) were the most common nonserious events, and discontinuation because of adverse events was higher with AR1001 (5.2% vs 1.7%).¹
AR1001 is an investigational once-daily, blood-brain barrier–penetrant phosphodiesterase 5 inhibitor. Phosphodiesterase 5 inhibitors, a class better known for erectile dysfunction and pulmonary arterial hypertension, block the enzyme that degrades cyclic guanosine monophosphate. The change in cerebrospinal fluid levels of that molecule at week 52 is consistent with target engagement.
Sharon J. Sha, MD, MS, global principal investigator, presented these results at the 2026 Clinical Trials on Alzheimer’s Disease conference in Boston. She said the CDR-SB result and safety profile were encouraging and that the secondary and biomarker findings warranted further evaluation alongside the overall result.¹ The open-label extension, in which all participants receive AR1001 30 mg, is expected to conclude in the third quarter of 2027.¹
Reference
1. AriBio’s oral AR1001 meets primary efficacy objective in prespecified monotherapy population in phase 3 POLARIS-AD trial. Press release. November 17, 2026. Accessed November 17, 2026.
Related to this article








